Report center

2024年中国特发性肺纤维化（IPF）治疗药物行业概览：创新肺纤维化靶向药物进入医保，患者端受益显著-头豹

特发性肺纤维化（Idiopathic Pulmonary Fibrosis，IPF）是一种原因不明，以弥漫性肺泡炎和肺泡结构紊乱最终导致肺间质纤维化为特征的疾病。IPF好发于中老年男性人群，主要表现为进行性加重的呼吸困难，伴限制性通气障碍和气体交换障碍，导致低氧血症、甚至呼吸衰竭，预后差，其肺组织学和胸部高分别率CT（HRCT）表现为普通型间质性肺炎(UIP)。 IPF患者基本无法治愈，治疗目的主

No subject companies

Publishers

头豹 View content →

Suggested next hops

Ranked by edge type and evidence strength (max 5). Prefer these over scrolling the full lists.

1头豹Published by or linked to this institution1
2Healthcare ServicesSame industry · 1 related reports1

Ask about this report neighborhood Read full report →

Other hot industries

Healthcare Services View content →

No related reports

← Back to knowledge graph